Skip to content
TrialMatch
Sign up
Recruiting

CUIMC Focal Therapy Registry

Create a profile to match View the full record on ClinicalTrials.gov

About this study

Patients undergoing high intensity focused ultrasound (HIFU) or irreversible electroporation (IRE) for prostate cancer will be invited to consent to have their data collected in a detailed comprehensive system to record and store patient, disease, and treatment-related characteristics. No treatment will be given, no randomization will occur, and each patient seen and treated for prostate cancer specifically with HIFU and IRE method in the Department of Urology division of Urologic Oncology within Columbia University Irving Medical Center will be eligible to be enrolled in the database.

Condition
Prostate Cancer
Tested
Focal therapy
Sponsor
Columbia University

Who can join

Age
40 to 85 years
Sex
Male only
Healthy volunteers
Not accepted

Inclusion 13

  • Minimum age: 40 years
  • Maximum age: 85 years
  • Eligible sex: Male
  • Study condition: Prostate Cancer
  • Organ-confined prostate adenocarcinoma diagnosed by MRI/ultrasound fusion biopsy within a multiparametric MRI derived region of interest
  • Clinical stage T2cN0M0 (radiological T3a is permitted)
  • Multi-parametric MRI at New York-Presbyterian hospital (NYPH) within the past 6 months demonstrating region of interest suspicion level 2 by the Prostate Imaging Reporting and Data System version 2.0 scoring criteria
  • Transrectal or transperineal ultrasound-guided biopsy with 10 template biopsy cores and 2 MRI-ultrasound fusion targeted biopsy cores from the above MRI-derived region of interest demonstrating:
  • histologically confirmed prostate adenocarcinoma from targeted biopsy cores
  • unilateral Gleason score 4+3 prostate adenocarcinoma
  • Age 40 to 85 years of age
  • Subjects choose to undergo focal therapy and decline alternative treatment (such as active surveillance, radical prostatectomy, radiation therapy, cryosurgery or hormone therapy)
  • Signed informed consent

Exclusion 10

  • Any Gleason score 4+4 outside an MRI-identified region of interest
  • Prostatic calcifications which in the opinion of the investigator would impede delivery of the energy to tumor in patients choosing HIFU
  • Any medical condition that would compromise the subject's ability to safely participate in the study
  • American Society of Anesthesiologists (ASA) criteria of IV or higher
  • Active urinary tract infection
  • Rectal fissure, fibrosis, stenosis, or other anatomic abnormality precluding insertion of transrectal device
  • Active, uncontrolled inflammatory bowel disease
  • Urinary tract or rectal fistula
  • Previous urethral sling, artificial urinary sphincter, or penile prosthesis surgery
  • Any contraindication to MRI (such as contrast allergy, sever claustrophobia, MRI-incompatible prosthesis)

Where

1 site, 1 recruiting

Columbia University Irving Medical Center

New York, New York, United States

Recruiting

Potential match only. Final eligibility is determined by the study team.